Dr. Floortje J. Backes, MD
Gynecologic Oncology (Gynecologic Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 22
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 173
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Gynecologic Oncology Physician primary
OH license 35.094277 -
Obstetrics & Gynecology Physician
OH license 35.094277
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Ohio State University State Health System Columbus, OH
- Blanchard Valley Hospital Findlay, OH
- Memorial Hospital Marysville, OH
Medical groups
- Osu Gyn and Ob Consultants LLC (70 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 173
- Services billed
- 640
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 180 | 55 |
| Established patient office or other outpatient visit, 30-39 minutes | 148 | 59 |
| Established patient office or other outpatient visit, 20-29 minutes | 63 | 45 |
| New patient office or other outpatient visit, 60-74 minutes | 51 | 51 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 37 | 27 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 35 | 19 |
| Hospital discharge day management, more than 30 minutes | 24 | 20 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 19 | 16 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | 15 | 11 |
| Imaging of lymph nodes during surgery | 12 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Lynparza (olaparib) | 30 |
| Letrozole Other prescribers in Hilliard, OH | 12 |
| Rubraca (rucaparib camsylate) | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 7 companies reported 14 payments worth $22,513 in total to this clinician.
| Genmab A/s | $9,280 |
|---|---|
| BioNTech SE | $4,060 |
| Genmab U.S., Inc. | $3,200 |
| Merck Sharp & Dohme LLC | $2,240 |
| AbbVie Inc. | $1,876 |
| AstraZeneca Pharmaceuticals LP | $1,805 |
| Tanabe Pharma America, Inc. | $51.40 |
| Consulting Fee | $12,853 |
|---|---|
| Travel and Lodging | $8,105 |
| Compensation for services other than consulting (speaking, faculty) | $1,200 |
| Food and Beverage | $356 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Genmab A/s Oct 16, 2025 | Travel and Lodging Tivdak · Oncology · travel to Berlin, DE, Germany · in-kind | $8,045 |
| BioNTech SE Jan 20, 2025 | Consulting Fee | $3,900 |
| Genmab U.S., Inc. Jul 25, 2025 | Consulting Fee Epkinly · Oncology · in-kind | $3,200 |
| Merck Sharp & Dohme LLC Jul 14, 2025 | Consulting Fee | $2,240 |
| AbbVie Inc. Nov 20, 2025 | Consulting Fee ELAHERE · ONCOLOGY | $1,800 |
| AstraZeneca Pharmaceuticals LP Jun 25, 2025 | Consulting Fee | $1,713 |
| Genmab A/s Oct 16, 2025 | Compensation for services other than consulting (speaking, faculty) Tivdak · Oncology | $1,200 |
| Genmab A/s Oct 16, 2025 | Travel and Lodging Tivdak · Oncology · travel to Berlin, DE, Germany | $34.72 |
| Tanabe Pharma America, Inc. May 31, 2025 | Travel and Lodging travel to Chicago, IL · in-kind | $24.60 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 8 industry-funded studies in 2025, from 4 companies. The companies reported $290,819 in research payments for these studies, mostly to the institutions running them.
- A Phase 3 Randomized, Open-label, Active-comparator Controlled Clinical Study of Pembrolizumab vs. Platinum Doublet Chemotherapy in Participants With Mismatch Repair Deficient dMMR Advanced or Recurrent Endometrial Ca…
Merck Sharp & Dohme LLC - A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) Versus Treatment of Investigator's Choice (IC) in Patients With Platinum Resistant Ovarian Cancer
Genmab U.S., Inc. - Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
AbbVie Inc. · Active, not recruiting · NCT05445778 - A Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination With Adjuvant Chemotherapy With or Without Radiotherapy for the Treatment of Newly Diagnosed High-Risk Endometrial Cancer After …
Merck Sharp & Dohme LLC - A Randomized, Phase 3, Double-Blind Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-risk, Locally Advanced Cervical Cancer KEYNOTE-A18 , ENGOT-cx11,GOG-3047
Merck Sharp & Dohme LLC - A global, retrospective, post-authorization study to characterize real
GlaxoSmithKline, LLC. - A phase 3, randomized, double-blind, multicenter study of dostarlimab
GlaxoSmithKline, LLC. - First in Human Study of IMGN151 in Recurrent Gynaecological Cancers
AbbVie Inc. · Active, not recruiting · NCT05527184
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.